Benedict Financial Advisors’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
Other funds holding GANX
PCM
Benedict Financial Advisors's GANX Position: Q3 2026 in Review
Benedict Financial Advisors reduced its Gain Therapeutics (GANX) stake by 61% in Q3 2026, selling an estimated $39.2K and leaving 13,500 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #136.
Benedict Financial Advisors first reported a position in GANX in Q4 2024 and has held it in 8 quarters since. The position peaked at $122K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.
- Benedict Financial Advisors held 13,500 shares of Gain Therapeutics worth $23.4K as of Q3 2026.
- Benedict Financial Advisors sold 21,500 Gain Therapeutics shares in Q3 2026, an estimated $39.2K.
- Gain Therapeutics made up ﹤0.01% of Benedict Financial Advisors's portfolio in Q3 2026, its #136 holding.
- Benedict Financial Advisors first reported a position in Gain Therapeutics in Q4 2024 and has held it in 8 quarters since.
- Benedict Financial Advisors's Gain Therapeutics position peaked at $122K in Q4 2025.
- 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.
Based on Benedict Financial Advisors's 13F filing for Q3 2026, filed 7 Oct 2026.